Dupixent and Narrowband UVB for Atopic Dermatitis
Recruiting
Phase 4
Interventional Study
Atopic Dermatitis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 40 (estimated)
- Sponsor
- Psoriasis Treatment Center of Central New Jersey · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Male or female adult ≥ 18 years of age;
* Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:
* EASI score of 16 or greater,
* IGA score of 3 or greater
* BSA of 10% or greater,
Exclusion Criteria:
* Subjects with previous exposure to dupiluma…
Contacts